{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:13:07Z","timestamp":1791825187229,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018967","name":"Universitat Pompeu Fabra","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018967","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study evaluated the activity of cefiderocol and the combination of ceftazidime\/avibactam (CZA) plus aztreonam against carbapenemase-producing extensively drug-resistant (XDR)\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    isolates. Nine clinical XDR\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    isolates with different sequence types and class A (GES) or B (VIM, IMP or NDM) carbapenemases were analysed. Time-kill assays assessed bacterial load reduction for each treatment, while chemostat experiments on four isolates validated these findings. All isolates showed resistance to CZA, with four also resistant to aztreonam. Seven isolates were susceptible to cefiderocol, but two displayed borderline susceptibility (MIC 2\u20134\u00a0mg\/L). Time-kill assays demonstrated bactericidal activity by cefiderocol in six isolates at 24\u00a0h, while CZA plus aztreonam showed bactericidal effects in three isolates and synergistic\/additive effects in four isolates. In the chemostat model, cefiderocol and CZA plus aztreonam were bactericidal in all four tested isolates, with cefiderocol showing greater bacterial reduction in three of these isolates. Both cefiderocol and CZA plus aztreonam achieved significant reductions in bacterial counts compared to controls, but there was no significant difference between cefiderocol monotherapy and the combination. Both cefiderocol and CZA plus aztreonam demonstrated activity against XDR\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    carrying metallo-\u03b2-lactamase (MBL) and\/or serine-\u03b2-lactamase (SBL) carbapenemases. Cefiderocol was the only consistently effective monotherapy with a bactericidal effect across all tested isolates in the chemostat model.\n                  <\/jats:p>","DOI":"10.1007\/s10096-025-05061-4","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T06:35:55Z","timestamp":1739860555000},"page":"1077-1087","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Addressing carbapenemase-producing extensively drug-resistant Pseudomonas aeruginosa: the potential of cefiderocol and ceftazidime\/avibactam plus aztreonam therapy"],"prefix":"10.1007","volume":"44","author":[{"given":"Mar\u00eda Milagro","family":"Montero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Domene-Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Prim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Ferola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"L\u00f3pez-Causap\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Gomis-Font","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario F.","family":"Ampuero-Morisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Echeverria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Sorl\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P.","family":"Horcajada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"5061_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1179\/2047773215Y.0000000030","volume":"109","author":"F Prestinaci","year":"2015","unstructured":"Prestinaci F, Pezzotti P, Pantosti A (2015) Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health 109:309\u2013318. https:\/\/doi.org\/10.1179\/2047773215Y.0000000030","journal-title":"Pathog Glob Health"},{"key":"5061_CR2","doi-asserted-by":"publisher","unstructured":"Azam MW, Khan AU (2019) Updates on the pathogenicity status of Pseudomonas aeruginosa. Drug Discov. Today 1(24):350\u20139. https:\/\/doi.org\/10.1016\/j.drudis.2018.07.003","DOI":"10.1016\/j.drudis.2018.07.003"},{"key":"5061_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/2049-632X.12033","volume":"67","author":"SL Gellatly","year":"2013","unstructured":"Gellatly SL, Hancock REW (2013) Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis 67:159\u2013173. https:\/\/doi.org\/10.1111\/2049-632X.12033","journal-title":"Pathog Dis"},{"key":"5061_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1159\/000490190","volume":"26","author":"A Rodrigo-Troyano","year":"2018","unstructured":"Rodrigo-Troyano A, Melo V, Marcos PJ, Laserna E, Peiro M, Suarez-Cuartin G et al (2018) Pseudomonas aeruginosa in chronic obstructive pulmonary disease patients with frequent hospitalized exacerbations: a prospective multicentre study. Respiration 26:96:417\u2013424. https:\/\/doi.org\/10.1159\/000490190","journal-title":"Respiration"},{"key":"5061_CR5","doi-asserted-by":"publisher","unstructured":"del Barrio-Tofi\u00f1o E, L\u00f3pez-Causap\u00e9 C, Oliver A (2020) Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired \u03b2-lactamases: 2020 update. Int J Antimicrob Agents 56. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106196","DOI":"10.1016\/j.ijantimicag.2020.106196"},{"key":"5061_CR6","doi-asserted-by":"publisher","unstructured":"Wang MG, Liu ZY, Liao XP, Sun RY, Li RB, Liu Y et al (2021) Retrospective data insight into the global distribution of carbapenemase-producing pseudomonas aeruginosa. Antibiotics 1:10. https:\/\/doi.org\/10.3390\/antibiotics10050548","DOI":"10.3390\/antibiotics10050548"},{"key":"5061_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/22221751.2022.2048972","volume":"11","author":"FC Tenover","year":"2022","unstructured":"Tenover FC, Nicolau DP, Gill CM (2022) Carbapenemase-producing Pseudomonas aeruginosa\u2013an emerging challenge. Emerg Microbes Infect 11:811\u2013814. https:\/\/doi.org\/10.1080\/22221751.2022.2048972","journal-title":"Emerg Microbes Infect"},{"key":"5061_CR8","doi-asserted-by":"publisher","unstructured":"Nordmann P, Poirel L Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria. Clin Infect Dis 2019 12;69:S521\u2013S528. https:\/\/doi.org\/10.1093\/cid\/ciz824","DOI":"10.1093\/cid\/ciz824"},{"key":"5061_CR9","doi-asserted-by":"publisher","unstructured":"Horcajada JP, Montero M, Oliver A, Sorl\u00ed L, Luque S, G\u00f3mez-Zorrilla S et al (2019) Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev 32. https:\/\/doi.org\/10.1128\/CMR.00031-19","DOI":"10.1128\/CMR.00031-19"},{"key":"5061_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1021\/acsmedchemlett.9b00534","volume":"11","author":"EM Gordon","year":"2020","unstructured":"Gordon EM, Duncton MAJ, Wang BJ, Qi L, Fan D, Li X et al (2020) Toward orally absorbed Prodrugs of the Antibiotic Aztreonam. Design of Novel Prodrugs of Sulfate containing drugs. Part 2. ACS Med Chem Lett 11:162\u2013165. https:\/\/doi.org\/10.1021\/acsmedchemlett.9b00534","journal-title":"ACS Med Chem Lett"},{"key":"5061_CR11","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1093\/jac\/dkw231","volume":"71","author":"C Ramsey","year":"2016","unstructured":"Ramsey C, MacGowan AP (2016) A review of the pharmacokinetics and pharmacodynamics of aztreonam. J Antimicrob Chemother 71:2704\u20132712. https:\/\/doi.org\/10.1093\/jac\/dkw231","journal-title":"J Antimicrob Chemother"},{"key":"5061_CR12","doi-asserted-by":"publisher","unstructured":"Wenzler E, Deraedt MF, Harrington AT, Danizger LH Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-\u03b2-lactamase-producing gram-negative pathogens. Diagn Microbiol Infect Dis 2017 1;88:352\u2013354. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.05.009","DOI":"10.1016\/j.diagmicrobio.2017.05.009"},{"key":"5061_CR13","doi-asserted-by":"publisher","unstructured":"Jorth P, McLean K, Ratjen A, Secor PR, Bautista GE, Ravishankar S et al (2017) Evolved aztreonam resistance is multifactorial and can produce hypervirulence in pseudomonas aeruginosa. MBio 8. https:\/\/doi.org\/10.1128\/mBio.00517-17","DOI":"10.1128\/mBio.00517-17"},{"key":"5061_CR14","doi-asserted-by":"publisher","unstructured":"Montero MM, Domene Ochoa S, L\u00f3pez-Causap\u00e9 C, Luque S, Sorl\u00ed L, Campillo N et al (2021) Time-kill evaluation of antibiotic combinations containing ceftazidime-avibactam against extensively drug-resistant Pseudomonas aeruginosa and their potential role against Ceftazidime-Avibactam-Resistant isolates. Microbiol Spectr 9. https:\/\/doi.org\/10.1128\/spectrum.00585-21","DOI":"10.1128\/spectrum.00585-21"},{"key":"5061_CR15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley M, Ceftazidime-Avibactam (2018) A review in the treatment of Serious Gram-negative bacterial infections. Drugs 78:675\u2013692. https:\/\/doi.org\/10.1007\/s40265-018-0902-x","journal-title":"Drugs"},{"key":"5061_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","volume":"1","author":"Y Wang","year":"2020","unstructured":"Wang Y, Wang J, Wang R, Cai Y (2020) Resistance to ceftazidime\u2013avibactam and underlying mechanisms. J Glob Antimicrob Resist 1:22:18\u201327. https:\/\/doi.org\/10.1016\/j.jgar.2019.12.009","journal-title":"J Glob Antimicrob Resist"},{"key":"5061_CR17","doi-asserted-by":"publisher","unstructured":"Lee M, Abbey T, Biagi M, Wenzler E (2021) Activity of aztreonam in combination with ceftazidime\u2013avibactam against serine- and metallo-\u03b2-lactamase\u2013producing Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 99. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115227","DOI":"10.1016\/j.diagmicrobio.2020.115227"},{"key":"5061_CR18","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s40265-021-01580-4","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed YY, Cefiderocol (2021) A review in Serious Gram-negative bacterial infections. Drugs 81:1559\u20131571. https:\/\/doi.org\/10.1007\/s40265-021-01580-4","journal-title":"Drugs"},{"key":"5061_CR19","doi-asserted-by":"publisher","unstructured":"Poole K, McKay GA (2003) Iron acquisition and its control in Pseudomonas aeruginosa: many roads lead to Rome. Front Biosci 8. https:\/\/doi.org\/10.2741\/1051","DOI":"10.2741\/1051"},{"key":"5061_CR20","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1128\/AAC.03098-15","volume":"160","author":"T Ito-Horiyama","year":"2016","unstructured":"Ito-Horiyama T, Ishii Y, Ito A, Sato T, Nakamura R, Fukuhara N et al (2016) Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother 160:4384\u20134386. https:\/\/doi.org\/10.1128\/AAC.03098-15","journal-title":"Antimicrob Agents Chemother"},{"key":"5061_CR21","doi-asserted-by":"publisher","first-page":"e01589","DOI":"10.1128\/AAC.01589-17","volume":"61","author":"E del Barrio-Tofi\u00f1o","year":"2017","unstructured":"del Barrio-Tofi\u00f1o E, L\u00f3pez-Causap\u00e9 C, Cabot G, Rivera A, Benito N, Segura C et al (2017) Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa isolates from Spain. Antimicrob Agents Chemother 61:e01589\u2013e01517. https:\/\/doi.org\/10.1128\/AAC.01589-17","journal-title":"Antimicrob Agents Chemother"},{"key":"5061_CR22","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/jac\/dkz147","volume":"74","author":"E Del Barrio-Tofin\u00f5","year":"2019","unstructured":"Del Barrio-Tofin\u00f5 E, Zamorano L, Cortes-Lara S, L\u00f3pez-Causape C, S\u00e1nchez-Diener I, Cabot G et al (2019) Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology. J Antimicrob Chemother 74:1825\u20131835. https:\/\/doi.org\/10.1093\/jac\/dkz147","journal-title":"J Antimicrob Chemother"},{"key":"5061_CR23","unstructured":"Committee E (2022) EUCAST: Clinical breakpoints and dosing of antibiotics [Internet]. Eur. Comm. Antimicrob. Susceptibility Test. [cited 2023 5] https:\/\/www.eucast.org\/clinical_breakpoints"},{"key":"5061_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.diagmicrobio.2019.03.003","volume":"94","author":"MA Hackel","year":"2019","unstructured":"Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF (2019) Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth. Diagn Microbiol Infect Dis 94:321\u2013325. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.03.003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"5061_CR25","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0149-2918(01)80103-X","volume":"23","author":"PF Smith","year":"2001","unstructured":"Smith PF, Ballow CH, Booker BM, Forrest A, Schentag JJ (2001) Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin Ther 23:1231\u20131244","journal-title":"Clin Ther"},{"key":"5061_CR26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/S00228-019-02804-Z","volume":"1","author":"S Das","year":"2020","unstructured":"Das S, Zhou D, Nichols WW, Townsend A, Newell P, Li J (2020) Selecting the dosage of ceftazidime\u2013avibactam in the perfect storm of nosocomial pneumonia. Eur J Clin Pharmacol 1:76:349. https:\/\/doi.org\/10.1007\/S00228-019-02804-Z","journal-title":"Eur J Clin Pharmacol"},{"key":"5061_CR27","doi-asserted-by":"publisher","unstructured":"Pavithra JYW, Jason S, Pogue M, Wu JY, Srinivas \u00c1P, Pogue JM Cefiderocol: a Novel Agent for the management of Multidrug-Resistant Gram-negative organisms. https:\/\/doi.org\/10.6084\/m9.figshare.11792034","DOI":"10.6084\/m9.figshare.11792034"},{"key":"5061_CR28","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1128\/AAC.03639-14","volume":"59","author":"T-P Lim","year":"2015","unstructured":"Lim T-P, Cai Y, Hong Y, Chan ECY, Suranthran S, Teo JQ-M et al (2015) In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 59:2515\u20132524. https:\/\/doi.org\/10.1128\/AAC.03639-14","journal-title":"Antimicrob Agents Chemother"},{"key":"5061_CR29","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1093\/jac\/dkv132","volume":"70","author":"R Singh","year":"2015","unstructured":"Singh R, Kim A, Angela Tanudra M, Harris JJ, McLaughlin RE, Patey S et al (2015) Pharmacokinetics\/pharmacodynamics of a \u03b2-lactam and \u03b2-lactamase inhibitor combination: a novel approach for aztreonam\/avibactam. J Antimicrob Chemother 70:2618\u20132626. https:\/\/doi.org\/10.1093\/jac\/dkv132","journal-title":"J Antimicrob Chemother"},{"key":"5061_CR30","doi-asserted-by":"publisher","unstructured":"Weber C, Schultze T, G\u00f6ttig S, Kessel J, Schr\u00f6der A, Tietgen M et al (2022) Antimicrobial activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa recovered at a German University Hospital. Microbiol Spectr 2610. https:\/\/doi.org\/10.1128\/spectrum.01697-22","DOI":"10.1128\/spectrum.01697-22"},{"key":"5061_CR31","doi-asserted-by":"publisher","unstructured":"Oueslati S, Bogaerts P, Dortet L, Bernabeu S, Ben Lakhal H, Longshaw C et al (2022) In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium. Antibiotics 1:11. https:\/\/doi.org\/10.3390\/antibiotics11101352","DOI":"10.3390\/antibiotics11101352"},{"key":"5061_CR32","doi-asserted-by":"publisher","unstructured":"Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R et al Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 2021 1;21:226\u2013240. https:\/\/doi.org\/10.1016\/S1473-3099(20)30796-9","DOI":"10.1016\/S1473-3099(20)30796-9"},{"key":"5061_CR33","doi-asserted-by":"publisher","unstructured":"Viale P, Sandrock CE, Ramirez P, Rossolini GM, Lodise TP (2023) Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence. Ann Intensive Care 113. https:\/\/doi.org\/10.1186\/s13613-023-01146-5","DOI":"10.1186\/s13613-023-01146-5"},{"key":"5061_CR34","doi-asserted-by":"publisher","unstructured":"Meschiari M, Volpi S, Faltoni M, Dolci G, Orlando G, Franceschini E et al (2021) Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections. JAC-Antimicrobial Resist 1:3. https:\/\/doi.org\/10.1093\/jacamr\/dlab188","DOI":"10.1093\/jacamr\/dlab188"},{"key":"5061_CR35","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s40121-023-00776-3","volume":"12","author":"\u00c1M Fendian","year":"2023","unstructured":"Fendian \u00c1M, Albanell-Fern\u00e1ndez M, Tuset M, Pitart C, Castro P, Soy D et al (2023) Real-Life Data on the effectiveness and safety of Cefiderocol in severely infected patients: a Case Series. Infect Dis Ther 12:1205\u20131216. https:\/\/doi.org\/10.1007\/s40121-023-00776-3","journal-title":"Infect Dis Ther"},{"key":"5061_CR36","doi-asserted-by":"publisher","unstructured":"Morroni G, Bressan R, Fioriti S, D\u2019achille G, Mingoia M, Cirioni O et al (2021) Antimicrobial activity of aztreonam in combination with old and new \u03b2-lactamase inhibitors against mbl and esbl co-producing gram-negative clinical isolates: Possible options for the treatment of complicated infections. Antibiotics 1:10. https:\/\/doi.org\/10.3390\/antibiotics10111341","DOI":"10.3390\/antibiotics10111341"},{"key":"5061_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1469-0691.2007.01861.x","volume":"14","author":"T Naas","year":"2008","unstructured":"Naas T, Poirel L, Nordmann P (2008) Minor extended-spectrum \u03b2-lactamases. Clin Microbiol Infect 14:42\u201352. https:\/\/doi.org\/10.1111\/j.1469-0691.2007.01861.x","journal-title":"Clin Microbiol Infect"},{"key":"5061_CR38","doi-asserted-by":"publisher","unstructured":"Wicky PH, Poiraud J, Alves M, Patrier J, D\u2019Humi\u00e8res C, L\u00ea M et al Cefiderocol Treatment for Severe Infections due to difficult-to-treat-resistant non-fermentative gram-negative Bacilli in ICU patients: a Case Series and Narrative Literature Review. Antibiot 2023 1;12:991. https:\/\/doi.org\/10.3390\/antibiotics12060991","DOI":"10.3390\/antibiotics12060991"},{"key":"5061_CR39","doi-asserted-by":"publisher","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ (2023) Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin. Infect. Dis 18. https:\/\/doi.org\/10.1093\/cid\/ciad428","DOI":"10.1093\/cid\/ciad428"},{"key":"5061_CR40","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1093\/jac\/dkad098","volume":"178","author":"Y Abouelhassan","year":"2023","unstructured":"Abouelhassan Y, Gill CM, Nicolau DP (2023) Assessing the in vivo efficacy of rational antibiotics and combinations against difficult-to-treat Pseudomonas aeruginosa producing GES \u03b2-lactamases. J Antimicrob Chemother 178:1843\u20131847. https:\/\/doi.org\/10.1093\/jac\/dkad098","journal-title":"J Antimicrob Chemother"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05061-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05061-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05061-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T08:54:39Z","timestamp":1746694479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05061-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["5061"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05061-4","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"MMM has received consulting fees and participated in educational activities from Pfizer, MSD, Shionogi, and Biomerieux. JPH has received consulting fees from Gilead, Tillots, Menarini and TFT Pharmaceuticals, and participated in educational activities from MSD, Pfizer and Angelini. A.O. has received fees as a speaker and\/or research grants from MSD, Shionogi, Pfizer and Wockhardt. All other authors have no potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}